Current Trends in Gynecologic Oncology

Mini Review Open Access

The Development of Chemotherapy Drugs and Cervical Cancer Screening Strategies

Jose Dorea*

School of Biosciences, The University of Porto is a Portuguese Public Research University Located in Porto, Portugal

Abstract

Chemotherapy has transformed cancer from a fatal illness that can only be cured with the right approach to a disease that can be treated and even cured in some cases. The reader will learn the fundamentals of the various chemotherapy drugs that are available through this activity; Additionally, it emphasizes the interprofessional team's contribution to the utilization of these agents. As may be obvious, there is impressive conflict overall about cervical disease screening procedures between nations that have comparative populace attributes. The fact that both positive and negative HPV results are frequently misinterpreted or overestimated is the primary issue with HPV testing-based strategies used in cervical cancer screening. A woman who is positive for HPV but negative for cytology should have both tests repeated. In point of fact, patients are more likely to undergo an immediate colposcopic examination far too frequently, which has the effect of increasing patients' anxiety, increasing healthcare costs, and possibly leading to an excessive number of treatments. Through mechanisms like cell cycle and metastasis inhibition, interleaved signaling, and others, cancer is treated with broader drugs. Anti-inflammatory, anti-atherogenic, anti-cancer, and anti-microbial properties of olivoropin, a polyphenol compound found throughout olivine, prevent the beginning of cancer progression. By preventing DNA from being subjected to oxidative stress, this essential function has anti-cyclic effects.

Chemothreapy drug (oleoropine)

The oleoropine properties of cancer in animals have demonstrated that the phenolic compounds in olive oil control the oxidative stress in the DNA of antimicrobial, proapoptotic, and apoptotic genes to prevent the various stages of cancer progression [1]. By cross-linking Stranded DNA, cyclophosphamide, an anti-neoplasmic agent, prevents cell division.

Oleuropein is made up of three components when it is extracted from oleoropine: glucose, phenolic acid, and hydroxytyrosol (3,4′-dihydroxyphenyl ethanol) [2]. The Memel olive tree's leaves were selected at random from the same Zanjan, Iran, tree. The Oleuropein results indicate that URPE is an important and very useful method of extracting natural products.

Two herbal preparations were used to test the developed method [3]. The oleuropein was successfully identified after HPLC was used to compare the elution time to a real standard. After that, the fractions were lyophilized and purified by HPLC. When compared to the genuine standard, the purity of the isolated oleuropein exceeded 90%.

Cell passage

Before washing the cells with PBS solution, transfer the petri-containing cell from the incubator to the hood and gently discard the cell medium after preparing the hood with all of the necessary equipment and materials for cell passage [4-7]. Dead cells and antitrypsin compounds are removed from the environment of the cells. After that, slowly pour 600 L of trypsin into cells, allowing it to reach all parts. The cells were then separated and made unicellular by gently inflating the flask, which was then incubated for three minutes until trypsin decomposed the adherent proteins and dissolved the cells in the bottom.

Cervical malignant growth screening

Beginning from May 1, 2017 in Australia the Public Cervical Screening Project will move from cervical cytology like clockwork, to HPV DNA testing as the sole essential screening test like clockwork in ladies matured 25 to 74 years, along with the execution of a functioning HPV immunization program [8,9]. In contrast, for population-based and opportunistic screening, cervical screening by cytology every two years is still recommended in Japan. In Europe, cervical cytology is recommended for women between the ages of 30 and 35, while HPV testing is the sole primary screening test for women between the ages of 30 and 35 every 5 to 10 years. Canadian guidelines also recommend cervical screening with cytology every 3 years. Actually, guidelines do not accurately reflect the actual situation in each European nation. Primary HPV testing is required every 5 years for women under 40 and every 10 years for women over 40 in the Netherlands, where screening is well-organized: Neither women under 30 nor those over 60 are eligible for screening. Different nations recommend HPV or cytology testing, and even within the same nation or region, there are significant differences. In fact, there are regions in Italy that use cytology, others that use HPV DNA testing, and one local health unit that only uses HPV mRNA testing [10]. However, some regions still do not have organized screening programs. In the U.S. rules for cervical malignant growth screening are very much organized and - in their work to arrive at most extreme expense viability - are explained into a few situations. Momentarily, cytology alone like clockwork is suggested for ladies under 30 years, while ladies matured 30 to 65 years may either keep screening with cervical cytology at regular intervals, or offered cotesting(cytology + HPV testing) if they need to be screened less much of the time [11-13]. Interestingly, European guidelines stipulate that only one primary test—HPV testing or cytology—should be used for cervical cancer screening at any age. In the United States, it is considered premature

***Corresponding author:** Jose Dorea, School of Biosciences, The University of Porto is a Portuguese public research university located in Porto, Portugal , E-mail: Dorea.J@gmail.com

Received: 02-Dec-2022, Manuscript No. ctgo-22-84802; **Editor assigned:** 05-Dec-2022, PreQC No. ctgo-22-84802 (PQ); **Reviewed:** 19-Dec-2022, QC No. ctgo-22-84802; **Revised:** 26-Dec-2022, Manuscript No. ctgo-22-84802 (R); **Published:** 02-Jan-2023, DOI: 10.4172/ctgo.1000135

Citation: Dorea J (2022) The Development of Chemotherapy Drugs and Cervical Cancer Screening Strategies. Current Trends Gynecol Oncol, 7: 135.

to use HPV testing alone as a valid screening strategy until additional data and algorithm development are made available. Because of this, the most recent version of the CDC guidelines, which was released in June 2015, states that HPV testing should not be performed as a stand-alone test in the screening process for cervical cancer (i.e., without a Pap test being performed simultaneously).

The ease with which the new algorithms are introduced exemplifies a feature that is often overlooked. They need to be easy to remember and put into practice because they should be addressed to all health care providers [14]. This is necessary to cut down on waste in the health care system, avoid overtreatments, which can lead to anxiety, problems with fertility, recurrence or persistence of the disease, and too many health care services. In well-established settings, the sensitivity of cervical cytology, which is frequently stated to be slightly more than 50%, is greater than 80%. Cytology has a higher positive predictive value and higher specificity than HPV testing. The authors of one study came to the conclusion that the increased sensitivity of the HPV test for high grade lesions reflects earlier detection rather than overdiagnosis after asserting that the cumulative incidence of high grade lesions over long-term follow-up was the same for both cytology and HPV screening [15]. In addition, lesions with a very slow rate of progression that could have been detected with repeat cytology a few years later should not be missed too early.

The patient's expectations and the tests taken can have an unintended impact on the decision-making process. With the widespread use of various molecular tests that are not applied consistently in accordance with shared recommendations, it is difficult to meet the expectations of women and doctors alike [16] it appears that the presumed benefits of HPV screening were outweighed by the impact on the economy, society, and mental health: the dangers are a misuse of assets, raise in expenses and tension, and under-acknowledgment of genuine sickness. On the off chance that we mean to furtherly lessen cervical malignant growth mortality, we want to:

- Implement HPV vaccination programs that include men and women as well as people of all ages.
- Increase screening program participation (avoiding over- and under-testing);
- Put cytology performance into practice, such as by using immunocytochemistry methods.
- Ensure that all women diagnosed with a high-grade cervical lesion receive adequate treatment and follow-up.

Conclusion

In conclusion, both developed and developing nations now acknowledge that cancer is the leading cause of death. Medical science has used toxic substances to fight cancer. Unintentional toxicities result when many treatments fail to distinguish between cancer cells and healthy cells. In this regard, numerous efforts have been made to identify and test antiangiogenic compounds for cancer treatment in recent years; The Mediterranean region, which has the lowest saturated fat content due to people's genetics and food habits, which is one of the most effective compounds, has a low prevalence of common cancers such as prostate and breast broad-spectrum drugs are discovered and used with mechanisms such as cell cycle inhibition, metastasis inhibition, enzyme inhibition, intercellular signaling inhibition, and others, to keep the treatment under control. The diet of the Mediterranean includes olive oil. Numerous studies show that the unsaturated lipid in the olive helps fight cancer. It has anti-inflammatory, antioxidant, anti-atherogenic, anticancer, anti-ischemic, fat-reducing, antimicrobial, and antiviral properties that have been used in medicine.

References

1. Fox H, Buckley CH (1982) The endometrial hyperplasias and their relationship to endometrial neoplasia. Histopathology Sep 6: 493-510.
2. Grimelius L (1968) A silver nitrate stain for alpha-2 cells in human pancreatic islets. Acta Soc Med Ups73: 243-270.
3. Burger RA, Brady MF, Bookman MA, Gini F Fleming, Bradley J Monk, et al. (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365: 2473-2483.
4. Albores-Saavedra J, Rodríguez-Martínez HA, Larraza-Hernández O (1979) Carcinoid tumors of the cervix. Pathol Annu 14: 273-291.
5. Ueda G, Yamasaki M, Inoue M, Tanaka Y, Kurachi K (1980) Immunohistological demonstration of calcitonin in endometrial carcinomas with and without argyrophil cells. Nihon Sanka Fujinka Gakkai Zasshi. 32: 960-964.
6. Tateishi R, Wada A, Hayakawa K, Hongo J, Ishii S (1975) Argyrophil cell carcinomas (apudomas) of the uterine cervix. Light and electron microscopic observations of 5 cases. Virchows Arch A Pathol Anat Histol 366: 257-274.
7. Proks C, Feit V(1982) Gastric carcinomas with argyrophil and argentaffin cells. Virchows Arch A Pathol Anat Histol 395: 201-206.
8. Partanen S, Syrjänen K. (1981) Argyrophilic cells in carcinoma of the female breast. Virchows Arch A Pathol Anat Histol 391: 45-51.
9. Fetissof F, Dubois MP, Arbeille-Brassart B, Lansac J, Jobard P (1983) Argyrophilic cells in mammary carcinoma. Hum Pathol 14:127-134.
10. Gibbs NM (1967) Incidence and significance of argentaffin and paneth cells in some tumours of the large intestine. J Clin Pathol 20: 826-831.
11. Azzopardi JG, Evans DJ (1971)Argentaffin cells in prostatic carcinoma: differentiation from lipofuscin and melanin in prostatic epithelium. J Pathol 104: 247-251.
12. Albores-Saavedra J, Rodríguez-Martínez HA, Larraza-Hernández O (1979) Carcinoid tumors of the cervix. Pathol Annu 14: 273-291.
13. Kubo T, Watanabe H Neoplastic argentaffin cells in gastric and intestinal carcinomas. Cancer 27: 447-454.
14. Jadoul P, Donnez J (2003) Conservative treatment may be beneficial for young women with atypical endometrial hyperplasia or endometrial adenocarcinoma. Fertil Steril 80: 1315-1324.
15. Evans-Metcalf ER, Brooks SE, Reale FR, Baker SP (1998) Profile of women 45 years of age and younger with endometrial cancer. Obstet Gynecol 91: 349-354.
16. Gluckman JL, McDonough J, Donegan JO, Crissman JD, Fullen W, et al. (1981) The free jejunal graft in head and neck reconstruction. Laryngoscope 91:1887-1895.